engleski

Recombinant factor VIIa in the treatment of hemostatic disorders in patients with solid tumors: Recombinant factor VIIa and solid tumors

In the University Hospital for Tumors, we used recombinant factor VIIa to treat 5 patients with solid tumors who developed severe bleeding during oncology treatment. Patients were aged 32 67 years, of which there were 4 men and one woman. Two men had a gastric cancer, one had a colon cancer, one the embryonic extragonadal tumor with metastases in the lungs and liver and one patient had breast cancer with liver metastases. Recombinant factor VIIa is a serine protease similar to trypsin, glycoprotein, consisting of 406 amino acids, that activates outer clotting path and initiates thrombin generation. It is applied for the purpose of stopping major bleeding in the states of disseminated intravascular coagulation (DIC) and when there is no other way to stop the bleeding. In our Institution it was used to stop bleeding in patients during irradiation, both, postoperativly and during chemotherapy in a single dose of 1.2 mg IV, after the standard treatment: SSplasm, cryoprecipitate, packed red blood cells and thrombocytes, could not have stopped the bleeding. The result was the momentary cessation of bleeding in patients. Recombinant factor VIIa can be successfully applied in oncology, in cases where conservative treatment of bleeding has no success.

bleeding; cancer; recombinant factor VIIa

nije evidentirano